Pharmacokinetics of irinotecan in combination with biweekly cetuximab in patients with advanced colorectal cancer.
The effect of biweekly cetuximab (CTX) on the pharmacokinetics of CPT-11 and its metabolites was evaluated in this prospective, paired, crossover study. Patients with epidermal growth factor receptor-positive advanced colorectal cancer received infusions of CPT-11 (180 mg/m(2); FOLFIRI schedule) every second week. CTX (500 mg/m(2) for 120 min) was infused on day 2, followed by biweekly infusions (500 mg/m(2) for 120 min). Plasma samples were analysed on day 1 of cycle 1 (CPT-11 monotherapy) and on day 1 of cycle 3 or 4 (CPT-11 plus CTX). The endpoint of this study was to evaluate differences in plasma concentrations of CPT-11 and metabolites between cycle 1 and cycle 3 (or 4). Generally, there was little difference in CPT-11 pharmacokinetics when combined with CTX in the 11 enrolled patients. However, a significantly lower area under the concentration-time curve from 0-48 hours was observed for the SN-38 glucuronide metabolite with combination therapy versus monotherapy (by 27%, p<0.05). CTX has no clinically relevant impact on the pharmacokinetics of CPT-11 or its activation into SN-38; however, there may be a delay in detoxification of SN-38 by beta-D-glucuronidation.